CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $250.56M, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.93×, lower than 95% of its Biotechnology peers (median 5.71×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
250.56MUSDvs all stocks (USD)
Revenue (TTM)
21.13MUSDvs all stocks (USD)
Profit Margin
-246.48%vs Biotechnology peers
Beta
1.59xvs all stocks
52-Week Change
-17.11%vs all stocks
Market Capitalization
250.56MUSDvs all stocks (USD)
Enterprise Value
216.39MUSDvs all stocks (USD)
Forward P/E
4.21xvs Biotechnology peers
Price to Sales (TTM)
14.31xvs Biotechnology peers
Price to Book (MRQ)
5.90xvs Biotechnology peers
Enterprise to Revenue
10.24xvs Biotechnology peers
Enterprise to EBITDA
-4.22xvs Biotechnology peers
Profit Margin
-246.48%vs Biotechnology peers
Operating Margin
7.89%vs Biotechnology peers
Return on Assets (TTM)
-16.04%vs Biotechnology peers
Return on Equity (TTM)
-78.53%vs Biotechnology peers
Revenue (TTM)
21.13MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1730USDUpdated Sep 26, 2026Quarterly Revenue Growth
1057.20%vs Biotechnology peers
Gross Profit (TTM)
-34.28MUSDvs all stocks (USD)
EBITDA (TTM)
-51.27MUSDvs all stocks (USD)
Net Income (TTM)
-52.08MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1057.20%vs Biotechnology peers
Operating Cash Flow (TTM)
-60.94MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-39.99MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.57MCHFFY2025 · Dec 31, 2025Operating Income
-68.86MCHF-83.12M · vs all stocks (USD)
Pre-tax Income
-70.45MCHFFY2025 · Dec 31, 2025Income Tax Expense
0.00CHFFY2025 · Dec 31, 2025Net Income
-70.45MCHFFY2025 · Dec 31, 2025EBIT
-70.26MCHFFY2025 · Dec 31, 2025EBITDA (Income Statement)
-64.50MCHFFY2025 · Dec 31, 2025Research & Development
56.44MCHFFY2025 · Dec 31, 2025Selling, General & Administrative
11.65MCHFFY2025 · Dec 31, 2025Other Operating Expenses
2.73MCHFFY2025 · Dec 31, 2025Non-operating Interest Income
1.86MCHFFY2025 · Dec 31, 2025Non-operating Interest Expense
191.00KCHFFY2025 · Dec 31, 2025EPS (Basic)
-0.7000CHFFY2025 · Dec 31, 2025EPS (Diluted)
-0.7000CHFFY2025 · Dec 31, 2025Basic Shares Outstanding
100.75MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
100.75MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-70.45MCHFFY2025 · Dec 31, 2025Operating Cash Flow
-65.28MCHFFY2025 · Dec 31, 2025Free Cash Flow
-66.17MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.80MCHFFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-70.45MCHFFY2025 · Dec 31, 2025Depreciation & Amortization
2.50MCHFFY2025 · Dec 31, 2025Stock-based Compensation
4.40MCHFFY2025 · Dec 31, 2025Other Non-cash Items
919.00KCHFFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
919.00KCHFFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.57MCHFFY2025 · Dec 31, 2025Capital Expenditures
-885.00KCHFFY2025 · Dec 31, 2025Other Investing Activity
-170.00KCHFFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.05MCHFFY2025 · Dec 31, 2025Long-term Debt Payments
-1.03MCHFFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.02MCHFFY2025 · Dec 31, 2025Shares Outstanding
99.43MSharesUpdated Sep 26, 2026Float Shares
39.19MSharesUpdated Sep 26, 2026Shares Short
3.48MSharesUpdated Sep 26, 2026Short Ratio
18.97daysvs all stocks
Short % of Shares Outstanding
7.48%vs all stocks
% Held by Insiders
37.97%vs all stocks
% Held by Institutions
24.45%vs all stocks
Total Cash (MRQ)
90.95MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7580USDUpdated Sep 26, 2026Total Debt (MRQ)
4.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1166xvs Biotechnology peers
Current Ratio (MRQ)
0.9320xvs Biotechnology peers
Book Value per Share (MRQ)
0.4274USDUpdated Sep 26, 2026Total Assets
154.25MCHF186.18M · vs all stocks (USD)
Total Current Assets
96.72MCHFFY2025 · Dec 31, 2025Total Liabilities
109.37MCHFFY2025 · Dec 31, 2025Total Non-current Assets
57.53MCHFFY2025 · Dec 31, 2025Total Non-current Liabilities
14.67MCHFFY2025 · Dec 31, 2025Total Current Liabilities
94.69MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents
26.80MCHFFY2025 · Dec 31, 2025Other Short-term Investments
64.62MCHFFY2025 · Dec 31, 2025Accounts Payable
2.07MCHFFY2025 · Dec 31, 2025Short-term Debt
852.00KCHFFY2025 · Dec 31, 2025Deferred Revenue
83.71MCHFFY2025 · Dec 31, 2025Long-term Debt
3.69MCHFFY2025 · Dec 31, 2025Common Stock (Book)
2.25MCHFFY2025 · Dec 31, 2025Retained Earnings
-439.02MCHFFY2025 · Dec 31, 2025Total Shareholders' Equity
44.88MCHF54.17M · vs all stocks (USD)
Treasury Stock
218.00KCHFFY2025 · Dec 31, 202552-Week Low
2.10USDUpdated Sep 26, 202652-Week High
4.00USDUpdated Sep 26, 202652-Week Change
-17.11%vs all stocks
Beta
1.59xvs all stocks
50-Day MA
2.55USDUpdated Sep 26, 2026200-Day MA
2.82USDUpdated Sep 26, 2026Avg 10-Day Volume
175.97KSharesUpdated Sep 26, 2026Avg 30-Day Volume
184.49KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.5200USDUpdated Sep 26, 2026Other Income / Expense
-3.26MCHFFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.93×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.93Industry median: 5.71Industry P5: 1.02Peers compared: 260
Financial Health
Altman Z-Score -4.3: distress zoneCritical
Altman Z-Score: -4.30
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $250.56M, lower than 95% of all stocks globallySignificant
Market cap (USD): 250,555,868Global P5: 275,556,405.438
Revenue is $21.13M, lower than 95% of all stocks globallySignificant
Revenue (USD): 21,131,261Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Lineage Cell Therapeutics Inc.
2 interpretationsIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Mesoblast Limited
2 interpretationsIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
XTL Biopharmaceuticals Ltd.
2 interpretationsIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC